RDY Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 июнь 2024 @ 23:00):
Our systems believe the stock currently is overvalued by -0.06% compare to its pairs and should correct downwards.

Stats
Объем за сегодня	248 553
Средний объем	244 927
Рыночная капитализация	12.69B
EPS	$78.49 ( Q4 \| 2024-06-12 )
Дата следующего отчета о доходах	( $1.100 ) 2024-07-24
Last Dividend	$0.488 ( 2023-07-28 )
Next Dividend	$0.407 ( 2024-07-30 )
P/E	19.05 (Sector) 49.64 (Industry) 35.32
ATR14	$0.0400 (0.05%)

ACB -2.33%

AMRX -1.09%

BHC 1.16%

CGC -3.30%

CTLT -0.32%

EBS -2.29%

ELAN 1.12%

EVO 5.03%

HEXO 2.45%

HLN -2.02%

LCI 0.00%

PRGO 0.98%

RDY 1.05%

TAK 0.23%

TARO 0.00%

TEVA -0.06%

ZTS -1.76%

Корреляция (AI algo v.1.1b): Overvalued: -0.06% $76.24 paired level. (Алгоритм отслеживает изменения наиболее коррелирующих акций в режиме реального времени и дает мгновенное обновление)

Объем Корреляция

Длинно: -0.51 (weak negative)

Кратко: -0.70 (moderate negative)

Signal:(28.546) Neutral

Dr. Reddy's Laboratories Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Dr. Reddy's Laboratories Корреляция - Валюта/Сырье

0.76
( moderate )

0.67
( moderate )

0.00
( neutral )

0.68
( moderate )

-0.60
( weak negative )

-0.51
( weak negative )

Dr. Reddy's Laboratories Финансовые показатели

Annual	2024
Выручка:	$279.16B
Валовая прибыль:	$163.61B (58.61 %)
EPS:	$335.22

FY	2024
Выручка:	$279.16B
Валовая прибыль:	$163.61B (58.61 %)
EPS:	$335.22

FY	2023
Выручка:	$245.88B
Валовая прибыль:	$202.97B (82.55 %)
EPS:	$271.47

FY	2022
Выручка:	$214.39B
Валовая прибыль:	$113.84B (53.10 %)
EPS:	$142.08

Financial Reports:

No articles found.

Dr. Reddy's Laboratories Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.765 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0.975 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0.479 (N/A)	$0 (N/A)

Dr. Reddy's Laboratories Dividend Information - Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.18 - Stable (23.59%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.0500	2001-11-20
Last Dividend	$0.488	2023-07-28
Next Dividend	$0.407	2024-07-30
Payout Date	2023-08-11
Next Payout Date	N/A
# dividends	27	--
Total Paid Out	$6.95	--
Avg. Dividend % Per Year	1.08%	--
Score	3.84	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.18
Div. Directional Score	8.81	--

Next Divdend (Est)
(2025-06-25)

$0.498 Estimate 6.22 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.84

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2001	$0.0500	0.99%
2002	$0.0260	0.27%
2003	$0.0535	0.54%
2004	$0.0545	0.34%
2005	$0.0575	0.58%
2006	$0.0545	0.50%
2007	$0.0920	0.51%
2008	$0.0980	0.54%
2009	$0.131	1.28%
2010	$0.240	0.97%
2011	$0.903	2.42%
2012	$0.229	0.76%
2013	$0.264	0.77%
2014	$0.303	0.75%
2015	$0.312	0.62%
2016	$0.297	0.65%
2017	$0.310	0.68%
2018	$0.297	0.78%
2019	$0.287	0.76%
2020	$0.333	0.82%
2021	$0.342	0.48%
2022	$0.765	1.17%
2023	$0.975	1.88%
2024	$0.479	0.68%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Dividend History

Ex Date	Amount	Declaration Date	Record Date	Payment Date
30 Jul 2024	$0.479	09 May 2024	15 Jul 2024	30 Nov -0001
28 Jul 2023	$0.488	11 May 2023	10 Jul 2023	11 Aug 2023
07 Jul 2023	$0.488	11 May 2023	10 Jul 2023	02 Jan 2024
01 Aug 2022	$0.378	24 May 2022	11 Jul 2022	12 Aug 2022
08 Jul 2022	$0.387	24 May 2022	11 Jul 2022	11 Jul 2022
08 Jul 2021	$0.342	16 Jun 2021	09 Jul 2021	11 Aug 2021
10 Jul 2020	$0.333	26 Jun 2020	13 Jul 2020	17 Aug 2020
12 Jul 2019	$0.287	30 Nov -0001	15 Jul 2019	15 Aug 2019
13 Jul 2018	$0.297	30 Nov -0001	16 Jul 2018	09 Aug 2018
13 Jul 2017	$0.310	06 Jun 2017	17 Jul 2017	10 Aug 2017
14 Jul 2016	$0.297	06 Jun 2016	18 Jul 2016	09 Aug 2016
08 Jul 2015	$0.312	30 Nov -0001	30 Nov -0001	17 Aug 2015
01 Aug 2014	$0.303	30 Nov -0001	30 Nov -0001	15 Aug 2014
10 Jul 2013	$0.264	30 Nov -0001	30 Nov -0001	15 Aug 2013
27 Jun 2012	$0.229	30 Nov -0001	30 Nov -0001	06 Aug 2012
29 Jun 2011	$0.251	30 Nov -0001	30 Nov -0001	11 Aug 2011
14 Jun 2011	$0.652	30 Nov -0001	30 Nov -0001	30 Nov -0001
30 Jun 2010	$0.240	30 Nov -0001	30 Nov -0001	30 Nov -0001
02 Jul 2009	$0.131	30 Nov -0001	30 Nov -0001	30 Nov -0001
03 Jul 2008	$0.0980	30 Nov -0001	30 Nov -0001	30 Nov -0001

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
ECC	Dividend Diamond	2024-07-11	Monthly	11	14.91%	9.72
BRW	Dividend Diamond	2024-06-11	Monthly	33	9.41%	9.26
VVR	Dividend Diamond	2024-06-18	Monthly	27	8.85%	9.19
FCT	Dividend Diamond	2024-06-03	Monthly	21	8.33%	9.14
PHK	Dividend Diamond	2024-06-13	Monthly	22	9.07%	9.13
SBR	Dividend Diamond	2024-06-17	Monthly	38	9.57%	9.10
XFLT	Dividend Diamond	2024-06-17	Monthly	8	10.49%	9.09
SRV	Dividend Royal	2024-07-16	Monthly	18	10.61%	9.04
FAM	Dividend Royal	2024-06-03	Monthly	20	8.07%	8.98
RA	Dividend Diamond	2024-06-11	Monthly	9	10.10%	8.93

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.199	1.500	6.01	9.02	[0 - 0.5]
returnOnAssetsTTM	0.144	1.200	5.21	6.25	[0 - 0.3]
returnOnEquityTTM	0.213	1.500	8.75	10.00	[0.1 - 1]
payoutRatioTTM	0.119	-1.000	8.81	-8.81	[0 - 1]
currentRatioTTM	2.58	0.800	2.09	1.669	[1 - 3]
quickRatioTTM	1.841	0.800	3.88	3.10	[0.8 - 2.5]
cashRatioTTM	0.0740	1.500	-0.700	-1.050	[0.2 - 2]
debtRatioTTM	0.0517	-1.500	9.14	-10.00	[0 - 0.6]
interestCoverageTTM	39.48	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	272.85	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	108.09	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.0714	-1.500	9.71	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.586	1.000	3.57	3.57	[0.2 - 0.8]
operatingProfitMarginTTM	0.242	1.000	7.16	7.16	[0.1 - 0.6]
cashFlowToDebtRatioTTM	2.27	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.720	0.800	8.53	6.82	[0.5 - 2]
Total Score				11.43

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	19.01	1.000	8.18	0	[1 - 100]
returnOnEquityTTM	0.213	2.50	9.19	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	108.09	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.0153	1.500	9.62	0	[0 - 0.4]
operatingCashFlowPerShareTTM	272.85	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.119	1.500	8.81	-8.81	[0 - 1]
pegRatioTTM	0.0183	1.500	-3.21	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.163	1.000	8.43	0	[0.1 - 0.5]
Total Score				6.18

Dr. Reddy's Laboratories Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Dr. Reddy's Laboratories

Dr. Reddy\'s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company\'s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy\'s Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.